NextCure, Inc. (NASDAQ:NXTC) Short Interest Up 48.9% in January

NextCure, Inc. (NASDAQ:NXTC) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 48,377 shares, a growth of 48.9% from the December 31st total of 32,483 shares. Currently, 1.6% of the shares of the company are short sold. Based on an average trading volume of 32,544 shares, the days-to-cover ratio is presently 1.5 days. Based on an average trading volume of 32,544 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.6% of the shares of the company are short sold.

Hedge Funds Weigh In On NextCure

A hedge fund recently raised its stake in NextCure stock. Cable Car Capital LP lifted its holdings in shares of NextCure, Inc. (NASDAQ:NXTC) by 13.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 758,141 shares of the company’s stock after purchasing an additional 88,040 shares during the quarter. Cable Car Capital LP owned about 28.29% of NextCure worth $349,000 as of its most recent filing with the SEC. Institutional investors own 42.65% of the company’s stock.

Analyst Ratings Changes

NXTC has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of NextCure in a report on Wednesday. Wall Street Zen raised shares of NextCure to a “hold” rating in a report on Saturday, December 13th. Finally, LADENBURG THALM/SH SH raised NextCure from a “neutral” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Friday, November 7th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.00.

NextCure Stock Up 4.1%

Shares of NASDAQ:NXTC opened at $10.85 on Friday. The business’s 50 day moving average is $12.56 and its 200 day moving average is $8.79. NextCure has a 52-week low of $2.69 and a 52-week high of $15.74. The stock has a market cap of $38.08 million, a P/E ratio of -0.45 and a beta of 1.52.

NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($3.22) EPS for the quarter, beating analysts’ consensus estimates of ($4.06) by $0.84. On average, sell-side analysts anticipate that NextCure will post -1.87 EPS for the current fiscal year.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.